FRANKFURT, Oct 23 (Reuters) - The CEO of Swiss pharmaceuticals giant Roche said competition authorities should not allow the controlling shareholder of Novo Nordisk
to acquiring contract drug manufacturer Catalent
.
"It's not a problem for us, but it could be a problem for other smaller players, if there is a restriction in how many (contract manufacturers) are available. From an industry perspective, it would be a wrong decision by authorities," Roche's CEO Thomas Schinecker said in a media call after the release of quarterly sales.
(Reporting by Ludwig Burger, Editing by Rachel More)
((ludwig.burger@thomsonreuters.com; +49 30 220133634;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。